AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA

Tokyo, June 24, 2018: AbbVie GK, Eisai Co., Ltd. and Eisai’s subsidiary for gastrointestinal diseases EA Pharma Co., Ltd.announced that the autoinjection delivery system for HUMIRA (generic name: adalimumab [recombinant], “HUMIRA”), HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL, was listed in the National Health Insurance Drug Price Standard on 30th May. AbbVie and Eisai have launched the products today. HUMIRA is a fully human anti-TNF-alpha monoclonal antibody formulation.

The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. The rounded pen-type body of this product is designed to fit in the hands of even patients who have a weak grip and conceal the needle tip when injected. In addition to the lock function and autoinjection delivery system which allows for the full amount drug injection in about 10 seconds, it features injection start and end alert sounds and an inspection window. The pen-type auto-injector devices are filled with the same drug solution as the conventional pre-filled syringe devices(1).

HUMIRA is the world’s first fully human anti-TNF-alpha monoclonal antibody and works by neutralizing TNF-alpha (tumor necrosis factor alpha), a protein that plays a central role in the inflammatory response of autoimmune diseases such as rheumatoid arthritis. HUMIRA is already used by one million patients in over one hundred countries.

AbbVie, Eisai and EA Pharma continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.

(1) HUMIRA for Subcutaneous Injection 40 mg Syringe 0.4 mL and HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL

Corporate Comm India(CCI Newswire)